

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/735273
				Filing Date	December 11, 2000
				First Named Inventor	Edwin A. Clark
				Art Unit	1634
				Examiner Name	J. C. Switzer
Sheet	1	of	2	Attorney Docket Number	WIBL-P01-534

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	CA	AN, Z, et al, "A clinical nude mouse metastatic model for highly malignant human pancreatic cancer."; Anticancer Res. 1996 Mar-Apr, 16(2):627-31			
	CB	AN, Z., et al, "Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor."; Clin Exp Metastasis. 1997 Mar; 15(2):184-95			
	CC	ANDERSON, ROBIN L.; "Peter MacCallum Cancer Institute, Genes Important in Breast Cancer Metastasis"; National Cancer Institute; Abstract 5R01CA090291-02 (2001)			
	CD	CHA, HEE-JAY, et al., "Role of Thymosin Beta4 in Tumor Metastasis and Angiogenesis," Journal of the National Cancer Institute, 95(22):1674-1680 (2003)			
	CE	CHER, MICHAEL; "Wayne State University Prostate Cancer, Bone Metastasis, and Metalloproteinases; National Institute of Cancer; Abstract 5R01CA088028-03 (2000)			
	CF	CHRISTENSEN, LISE, "The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix," APMIS Suppl. 26(100):6-36 (1992)			
	CG	FRANKE, F.E., et al., "Association between Fibronectin Expression and Prognosis in Ovarian Carcinoma," Anticancer Research, 23:4261-4267 (2003)			
	CH	GOLDSTEIN, ALLAN L., "Thymosin Beta4: A New Molecular Target for Antitumor Strategies," Journal of the National Cancer Institute, 95(22):1646-1647 (2003)			
	CI	IOACHIM, E., et al., "Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression," European Journal of Cancer, 38:2362-2370 (2002)			
	CJ	LIU, CONG-RONG, et al., "Differential thymosin beta10 expression levels and actin filament organization in tumor cell lines with different metastatic potential," Chinese Medical Journal, 117(2):213-218 (2004)			
	CK	MARGALIT, O., et al., "Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines," British Journal of Cancer, 89:314-319 (2003)			
	CL	QUENTIN, THOMAS, et al., "Alteration of the Vascular Endothelial Growth Factor and Angiopoietins-1 and -2 Pathways in Transitional Cell Carcinomas of the Urinary Bladder			


Examiner Signature		Date Considered	6/1/05
-----------------------	--	--------------------	--------

Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	09/735273
				Filing Date	December 11, 2000
				First Named Inventor	Edwin A. Clark
				Art Unit	1634
				Examiner Name	J. C. Switzer
Sheet	2	of	2	Attorney Docket Number	WIBL-P01-534

		Associated with Tumor Progression," Anticancer Research, 24:2745-2756 (2004)	
	CM	RIDLEY, ANNE, "Molecular switches in metastasis," Nature, 406:466-467 (2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	6/11/05
-----------------------	---	--------------------	---------